BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Akili Interactive (“Akili”), a leading digital medicine company creating prescription treatments for people living with cognitive dysfunction and brain-related ...
Akili’s flagship product is a prescription digital treatment to address inattention in children with attention deficit hyperactivity disorder (ADHD). Akili’s patented technology serves as the ...
Akili, a company that makes a video game treatment for ADHD, will sell to Virtual Therapeutics for about $34 million, according to a Wednesday regulatory filing. The two companies will merge into a ...
Following positive top-line data released in May, Akili Interactive announced it will release its video game treatment for attention deficit hyperactivity disorder to adults who want to use it.
Akili Interactive, the Boston maker of a Food and Drug Administration-cleared video game to treat ADHD, has long been bullish on the tremendous potential of its technology to reach wide swaths of the ...
A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal ...
Akili, the company behind video game-like prescription and over-the-counter digital therapeutics for individuals with ADHD, has signed a definitive merger agreement with mental health and fitness ...
Editor's note: The original version of this story claimed that STARS-ADHD Adjunctive enrolled 2016 subjects, instead of 206. We apologize for this error. Digital ...
If you want to know who really controls Akili, Inc. (NASDAQ:AKLI), then you'll have to look at the makeup of its share registry. With 26% stake, individual investors possess the maximum shares in the ...
Maker of the first-and-only FDA-cleared prescription video game treatment joins the ranks of Canva, Microsoft, SpaceX, and more BOSTON--(BUSINESS WIRE)-- Akili Interactive Labs, Inc. (“Akili”), a ...
Digital medicine company Akili is listed on the Nasdaq Stock Market following a business combination with Social Capital Suvretta Holdings that raised $163 million. Akili began trading on the Nasdaq ...
Chamath Palihapitiya Announces SPAC Deal For Akili: Revolutionary Digital Therapy For Mental Illness
A biotech focused SPAC launched by frequent SPAC sponsor Chamath Palihapitiya announced a merger deal Wednesday morning. The deal includes a PIPE of $162 million, with $100 million of the total coming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results